A team from the Santa Fe Institute, Arizona State University, and Slum Dwellers International has been selected to develop a new way to empower the world's poorest, most vulnerable communities.
A technology invented by faculty at LSU Health New Orleans is part of an acquisition deal by Allergan plc, a global pharmaceutical company. Allergan acquired Anterios, a clinical stage pharmaceutical company, which licensed an LSU Health-patented technology in 2008 and in which LSU Health New Orleans held equity. The technology is for the use of topical botulinum toxin to treat or prevent acne.
The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the US.
In collaboration with the Coreplast Laitila company, VTT Technical Research Centre of Finland has created a reflector that can be wirelessly controlled via a mobile phone application.
Full GenomesTM Corporation, the first company to offer a high-resolution and comprehensive Y chromosome test in January 2013, announced today that it is collaborating with Novogene, a leading genomics solution provider with the largest Illumina-based sequencing capacity in China, to offer GenomeGuide , one of the first whole genome tests for ancestry purposes for under $1,000.
Researchers at The University of Texas at Arlington and The University of Texas at Austin are developing a solution in the form of what are believed to be the first formal protocols for effective and safe use of cold therapy, and a state-of-the-art cryotherapy device that can stimulate blood flow to keep tissue healthy and minimize potential side effects.
NewYork-Presbyterian, Columbia University Medical Center and Weill Cornell Medicine are among the nation's top cancer centers calling for increased human papillomavirus (HPV) vaccination for the prevention of cancer. The statement comes in response to the public health threat posed by low national vaccination rates for HPV. The centers are urging physicians, parents and young adults to take advantage of this opportunity to prevent many types of cancer.
Biotechnology startup CosmosID has successfully closed it's Series B by receiving $6 million in funding from Applied Value Group. CosmosID is the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-generation DNA sequencing.
Beginning January 2016, Oxford University Press (OUP) is the proud publisher of the prestigious Journal of Neuropathology & Experimental Neurology (JNEN).
In response to low national vaccination rates for the human papillomavirus (HPV), The University of Texas MD Anderson Cancer Center has joined with the 68 other National Cancer Institute (NCI)-designated cancer centers in issuing a statement calling for increased HPV vaccination for the prevention of cancer.